Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients

Björn Nashan, Robert Gaston, Vincent Emery, Marcus D. Säemann, Nicolas J. Mueller, Lionel Couzi, Jacques Dantal, Fuad Shihab, Shamkant Mulgaonkar, Yu Seun Kim, Daniel Brennan

Research output: Contribution to journalReview article

Abstract

Cytomegalovirus (CMV) infection and disease are major complications in the renal transplant recipient. The occurrence of CMV is associated with acute rejection, allograft dysfunction, significant end-organ disease, and mortality. Several clinical studies have indicated that the use of certain immunosuppressive drugs can delay the reconstitution of CMV-specific cell-mediated immune responses, thereby leading to uncontrolled CMV replication. Accumulating evidence indicates, however, that the use of the mammalian target of rapamycin (mTOR) inhibitors, sirolimus, and everolimus, may decrease the incidence and severity of CMV infection in renal transplant recipients. The purpose of this article is to review CMV infection data from randomized clinical trials that investigated the use of sirolimus-and everolimus-based treatment regimens in de novo renal transplantation. The mTOR inhibitor clinical trials included were primarily identified using biomedical literature database searches, with additional studies added at the authors' discretion. This review will summarize these studies to discuss whether mTOR inhibitor-based immunosuppressive therapy can reduce the magnitude of CMV-related complications in the de novo renal transplantation setting.

Original languageEnglish (US)
Pages (from-to)1075-1085
Number of pages11
JournalTransplantation
Volume93
Issue number11
DOIs
StatePublished - Jun 15 2012
Externally publishedYes

Fingerprint

Cytomegalovirus Infections
Sirolimus
Immunosuppressive Agents
Cytomegalovirus
Kidney
Kidney Transplantation
Therapeutics
Allografts
Randomized Controlled Trials
Transplant Recipients
Clinical Trials
Databases
Mortality
Incidence
Pharmaceutical Preparations
Everolimus

Keywords

  • Anti-CMV mechanism of action
  • Cytomegalovirus (CMV)
  • Everolimus
  • Mammalian target of rapamycin (mTOR) inhibitors
  • Sirolimus

ASJC Scopus subject areas

  • Transplantation

Cite this

Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. / Nashan, Björn; Gaston, Robert; Emery, Vincent; Säemann, Marcus D.; Mueller, Nicolas J.; Couzi, Lionel; Dantal, Jacques; Shihab, Fuad; Mulgaonkar, Shamkant; Seun Kim, Yu; Brennan, Daniel.

In: Transplantation, Vol. 93, No. 11, 15.06.2012, p. 1075-1085.

Research output: Contribution to journalReview article

Nashan, B, Gaston, R, Emery, V, Säemann, MD, Mueller, NJ, Couzi, L, Dantal, J, Shihab, F, Mulgaonkar, S, Seun Kim, Y & Brennan, D 2012, 'Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients', Transplantation, vol. 93, no. 11, pp. 1075-1085. https://doi.org/10.1097/TP.0b013e31824810e6
Nashan, Björn ; Gaston, Robert ; Emery, Vincent ; Säemann, Marcus D. ; Mueller, Nicolas J. ; Couzi, Lionel ; Dantal, Jacques ; Shihab, Fuad ; Mulgaonkar, Shamkant ; Seun Kim, Yu ; Brennan, Daniel. / Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. In: Transplantation. 2012 ; Vol. 93, No. 11. pp. 1075-1085.
@article{d03f69f8bc37496a97f0a5f987ddd236,
title = "Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients",
abstract = "Cytomegalovirus (CMV) infection and disease are major complications in the renal transplant recipient. The occurrence of CMV is associated with acute rejection, allograft dysfunction, significant end-organ disease, and mortality. Several clinical studies have indicated that the use of certain immunosuppressive drugs can delay the reconstitution of CMV-specific cell-mediated immune responses, thereby leading to uncontrolled CMV replication. Accumulating evidence indicates, however, that the use of the mammalian target of rapamycin (mTOR) inhibitors, sirolimus, and everolimus, may decrease the incidence and severity of CMV infection in renal transplant recipients. The purpose of this article is to review CMV infection data from randomized clinical trials that investigated the use of sirolimus-and everolimus-based treatment regimens in de novo renal transplantation. The mTOR inhibitor clinical trials included were primarily identified using biomedical literature database searches, with additional studies added at the authors' discretion. This review will summarize these studies to discuss whether mTOR inhibitor-based immunosuppressive therapy can reduce the magnitude of CMV-related complications in the de novo renal transplantation setting.",
keywords = "Anti-CMV mechanism of action, Cytomegalovirus (CMV), Everolimus, Mammalian target of rapamycin (mTOR) inhibitors, Sirolimus",
author = "Bj{\"o}rn Nashan and Robert Gaston and Vincent Emery and S{\"a}emann, {Marcus D.} and Mueller, {Nicolas J.} and Lionel Couzi and Jacques Dantal and Fuad Shihab and Shamkant Mulgaonkar and {Seun Kim}, Yu and Daniel Brennan",
year = "2012",
month = "6",
day = "15",
doi = "10.1097/TP.0b013e31824810e6",
language = "English (US)",
volume = "93",
pages = "1075--1085",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients

AU - Nashan, Björn

AU - Gaston, Robert

AU - Emery, Vincent

AU - Säemann, Marcus D.

AU - Mueller, Nicolas J.

AU - Couzi, Lionel

AU - Dantal, Jacques

AU - Shihab, Fuad

AU - Mulgaonkar, Shamkant

AU - Seun Kim, Yu

AU - Brennan, Daniel

PY - 2012/6/15

Y1 - 2012/6/15

N2 - Cytomegalovirus (CMV) infection and disease are major complications in the renal transplant recipient. The occurrence of CMV is associated with acute rejection, allograft dysfunction, significant end-organ disease, and mortality. Several clinical studies have indicated that the use of certain immunosuppressive drugs can delay the reconstitution of CMV-specific cell-mediated immune responses, thereby leading to uncontrolled CMV replication. Accumulating evidence indicates, however, that the use of the mammalian target of rapamycin (mTOR) inhibitors, sirolimus, and everolimus, may decrease the incidence and severity of CMV infection in renal transplant recipients. The purpose of this article is to review CMV infection data from randomized clinical trials that investigated the use of sirolimus-and everolimus-based treatment regimens in de novo renal transplantation. The mTOR inhibitor clinical trials included were primarily identified using biomedical literature database searches, with additional studies added at the authors' discretion. This review will summarize these studies to discuss whether mTOR inhibitor-based immunosuppressive therapy can reduce the magnitude of CMV-related complications in the de novo renal transplantation setting.

AB - Cytomegalovirus (CMV) infection and disease are major complications in the renal transplant recipient. The occurrence of CMV is associated with acute rejection, allograft dysfunction, significant end-organ disease, and mortality. Several clinical studies have indicated that the use of certain immunosuppressive drugs can delay the reconstitution of CMV-specific cell-mediated immune responses, thereby leading to uncontrolled CMV replication. Accumulating evidence indicates, however, that the use of the mammalian target of rapamycin (mTOR) inhibitors, sirolimus, and everolimus, may decrease the incidence and severity of CMV infection in renal transplant recipients. The purpose of this article is to review CMV infection data from randomized clinical trials that investigated the use of sirolimus-and everolimus-based treatment regimens in de novo renal transplantation. The mTOR inhibitor clinical trials included were primarily identified using biomedical literature database searches, with additional studies added at the authors' discretion. This review will summarize these studies to discuss whether mTOR inhibitor-based immunosuppressive therapy can reduce the magnitude of CMV-related complications in the de novo renal transplantation setting.

KW - Anti-CMV mechanism of action

KW - Cytomegalovirus (CMV)

KW - Everolimus

KW - Mammalian target of rapamycin (mTOR) inhibitors

KW - Sirolimus

UR - http://www.scopus.com/inward/record.url?scp=84862290097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862290097&partnerID=8YFLogxK

U2 - 10.1097/TP.0b013e31824810e6

DO - 10.1097/TP.0b013e31824810e6

M3 - Review article

VL - 93

SP - 1075

EP - 1085

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 11

ER -